PlainPharmaWatch

CMS Open Payments · Tool

Alcon Research LLC vs Axsome Therapeutics, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Alcon Research LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 3,482, versus 45 for the other company. Its single largest recorded recipient represents 0.6% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Alcon Research LLC
HHI 3,482 · top recipient 0.6%
Ranked #504 of 1,838 companies by HHI
Axsome Therapeutics, Inc.
HHI 45 · top recipient 0.0%
Ranked #1,768 of 1,838 companies by HHI

Payment Overview

Company A

Alcon Research LLC

Total Payments
$23.7M
% of Industry
0.2%
Transactions
7,282
Avg per Transaction
$3.3K
Recipients
795
Avg per Recipient
$29.8K
Payment Types
8
Top Payment Type
Acquisitions
Total Payments
$23.6M
% of Industry
0.2%
Transactions
80,352
Avg per Transaction
$293.15
Recipients
79,802
Avg per Recipient
$295.17
Payment Types
6
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

Alcon Research LLC vs Axsome Therapeutics, Inc. - total reported payments in CMS Open Payments PY2024

Alcon Research LLC$23.7MAxsome Therapeutics, Inc.$23.6M

Payment Types Breakdown

Alcon Research LLC

Acquisitions $4.1M

17.4%

Consulting Fee $1.4M

5.9%

Royalty or License $753.8K

3.2%

Grant $625.0K

2.6%

Compensation for Services Other Than Consulting $88.2K

0.4%

Travel and Lodging $80.6K

0.3%

Axsome Therapeutics, Inc.

Consulting Fee $8.7M

36.7%

Food and Beverage $2.4M

10.1%

Travel and Lodging $945.4K

4.0%

Compensation for Faculty or Speaker (Medical Education) $239.3K

1.0%

Education $4.2K

0.0%

Space Rental or Facility Fees $3.5K

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Alcon Research LLC

  1. 1

    MARK C LOBANOFF

    $4,133,000.00 · 2 txns

  2. 2

    Guy Kezirian

    $453,750.00 · 1 txns

  3. 3

    STEVE T CHARLES

    $428,019.49 · 28 txns

  4. 4

    Uci Medical Center

    $257,906.50 · 4 txns

  5. 5

    ANDREW W BROWNE

    $75,000.00 · 1 txns

Axsome Therapeutics, Inc.

  1. 1

    LEON ROSENBERG

    $249,399.95 · 22 txns

  2. 2

    GREGORY MATTINGLEY

    $175,349.15 · 164 txns

  3. 3

    SCOTT WIENER

    $162,397.43 · 234 txns

  4. 4

    CRAIG CHEPKE

    $152,275.59 · 118 txns

  5. 5

    ANDREW CUTLER

    $149,850.96 · 133 txns

Summary Comparison

Metric Alcon Research LLC Axsome Therapeutics, Inc.
Total Payments $23.7M $23.6M
% of Industry Total 0.2% 0.2%
Transaction Count 7,282 80,352
Avg per Transaction $3.3K $293.15
Recipient Count 795 79,802
Avg per Recipient $29.8K $295.17
Payment Type Count 8 6
Top Payment Type Acquisitions Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.